0001415889-22-006744.txt : 20220617 0001415889-22-006744.hdr.sgml : 20220617 20220617163033 ACCESSION NUMBER: 0001415889-22-006744 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220615 FILED AS OF DATE: 20220617 DATE AS OF CHANGE: 20220617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clancy Paul J CENTRAL INDEX KEY: 0001409601 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40925 FILM NUMBER: 221024298 MAIL ADDRESS: STREET 1: C/O BIOGEN IDEC INC. STREET 2: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xilio Therapeutics, Inc. CENTRAL INDEX KEY: 0001840233 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851623397 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-833-1027 MAIL ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-06172022_040611.xml X0306 4 2022-06-15 0001840233 Xilio Therapeutics, Inc. XLO 0001409601 Clancy Paul J 828 WINTER STREET SUITE 300 WALTHAM MA 02451 true false false false Stock Option (right to buy) 2.28 2022-06-15 4 A 0 13200 0 A 2032-06-14 Common Stock 13200 13200 D The option award was granted on June 15, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 15, 2023 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date. /s/ Chris Frankenfield, Attorney-in-Fact 2022-06-17